Zobrazeno 71 - 80
of 403
pro vyhledávání: '"Diamant Thaçi"'
Autor:
Ralf Ludwig, Diamant Thaçi, Detlef Zillikens, Michael Kasperkiewicz, Artem Vorobyev, Enno Schmidt, Sascha Ständer
Publikováno v:
The Journal of Dermatology. 48:1257-1261
Bullous pemphigoid (BP) is an autoimmune skin disease, caused by autoantibodies to BP180 and/or BP230. While both these autoantigens are expressed in the entire skin, only some parts of the body become affected. Rare clinical observations indicate th
Autor:
Richard B, Warren, Michael, Gold, Melinda, Gooderham, Leon H, Kircik, Jean-Philippe, Lacour, Philip, Laws, Monika, Liljedahl, Charles, Lynde, Marie Holst, Mørch, Wiebke, Sondermann, Diamant, Thaçi
Publikováno v:
Journal of Drugs in Dermatology. 20:436-441
Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid relief of symptoms followed by long-term management to maintain remission. This 4-week open-label phase of a long-term proactive
Autor:
Meng Zhang, Brad Shumel, Faisal A. Khokhar, Zafer E. Ozturk, Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Marjolein S. de Bruin-Weller, Zhen Chen
Publikováno v:
Beck, L A, Thaçi, D, Deleuran, M, de Bruin-Weller, M, Chen, Z, Khokhar, F A, Zhang, M, Ozturk, Z E & Shumel, B 2022, ' Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis : results from an open-label extension study ', Journal of Dermatological Treatment, vol. 33, no. 3, pp. 1608-1616 . https://doi.org/10.1080/09546634.2020.1871463
BACKGROUND: Most systemic agents used for moderate-to-severe atopic dermatitis (AD) may lead to adverse events requiring routine laboratory monitoring, increasing patient burden and possibly decreasing treatment adherence.OBJECTIVE: To evaluate clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c67e84b9721182b828b18a88e61ee9b
https://pure.au.dk/portal/da/publications/laboratory-safety-of-dupilumab-for-up-to-3-years-in-adults-with-moderatetosevere-atopic-dermatitis(7fe39251-db3f-47a2-9c82-30d768712c56).html
https://pure.au.dk/portal/da/publications/laboratory-safety-of-dupilumab-for-up-to-3-years-in-adults-with-moderatetosevere-atopic-dermatitis(7fe39251-db3f-47a2-9c82-30d768712c56).html
Autor:
T. Bieber, Margaret Gamalo, Fabio P. Nunes, Norito Katoh, Diamant Thaçi, Maher Issa, Kristian Reich, Dennis Brinker, Jamie Weisman, Eric L. Simpson, E. Riedl, Antonio Torrelo, M S de Bruin-Weller, Jacob P. Thyssen, Robert Bissonnette, Katrin Holzwarth, Melinda Gooderham, Jonathan Janes
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 35:476-485
Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in la
Autor:
F Brock, Yves Poulin, Alice B. Gottlieb, Richard B. Warren, Andrew Blauvelt, M Boehnlein, C. Leonardi, Kenneth B. Gordon, Kristian Reich, Diamant Thaçi, C Ecoffet
Publikováno v:
British Journal of Dermatology. 184:652-662
Background Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic. Objectives To report the 3-year efficacy of CZP in plaque psoriasis, pooled from the CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) phase III tria
Autor:
Bernard Gershater, Katja Bieber, Artem Vorobyev, Marlene A. Ludwig, Henner Zirpel, David A. De Luca, Diamant Thaci, Khalaf Kridin, Ralf J. Ludwig
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectivesThis study investigated psoriatic arthritis (PsA) risk across varied psoriasis manifestations, considering sex and ethnicity.MethodsUsing TriNetX, a federated database encompassing over 120 million electronic health records (EHRs), we perfo
Externí odkaz:
https://doaj.org/article/4804b69f84bb4be2b09b0054fc52b7e2
Autor:
Wolf-Henning Boehncke, Julie Birt, L Steve Lobosco, William Tillett, Elizabeth Holdsworth, Gary Milligan, Joseph F. Merola, Matthew M. Hufford, Nicola Booth, Diamant Thaçi
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 3, Pp 617-637 (2020)
Rheumatology and Therapy, Vol. 7, No 3 (2020) pp. 617-637
Rheumatology and Therapy
Rheumatology and Therapy, Vol. 7, No 3 (2020) pp. 617-637
Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory disease where disease burden and quality of life (QoL) are affected by both joint and skin manifestations. Methods Patient and physician reported data were collected about 32
Autor:
Kim Papp, Joseph Wu, Peter Nash, Wolf-Henning Boehncke, Joseph F. Merola, M-A Hsu, Jordi Gratacós, Daniela Graham, Cunshan Wang, P. Young, Diamant Thaçi
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Background Psoriatic arthritis (PsA) is a chronic, systemic immune‐mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the trea
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology. 13:495-498
During the 28th Congress of the European Academy of Dermatology and Venereology (EADV) held in Madrid in October 2019, an industry hub was dedicated to the long-term management of psoriasis. Psoriasis is a systemic inflammatory disease primarily invo
Autor:
Detlef Zillikens, Nadine Kuznik, Ralf Ludwig, Iakov Shimanovich, Diamant Thaçi, Bálint Kovács, Ellen Rose
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 18:618-624